- Mirum Pharmaceuticals (NASDAQ:MIRM) receives a bullish price target from RBC Capital amidst revenue growth driven by Livmarli and bile acid drugs.
- The company reported a 50% increase in revenues for the fourth quarter, despite a net loss, showcasing strong sales performance.
- MIRM’s stock shows significant volatility with a current price of $92.22, reflecting a 15.10% decrease, yet it maintains a market capitalization of approximately $4.77 billion.
Mirum Pharmaceuticals (NASDAQ:MIRM) is a biopharmaceutical company focused on developing and commercializing therapies for rare liver diseases. The company is known for its innovative treatments, including Livmarli and bile acid drugs, which have contributed significantly to its revenue growth. In a competitive landscape, Mirum stands out with its specialized focus on liver conditions.
On February 26, 2026, Joe Kim from RBC Capital set a price target of $128 for MIRM. At that time, the stock was trading at $94.14, suggesting a potential upside of about 36%. This optimistic outlook reflects confidence in Mirum’s growth prospects, despite recent financial challenges.
Mirum reported a loss for the fourth quarter, but experienced a 50% increase in revenues. This growth was driven by strong sales of Livmarli and bile acid drugs, exceeding estimates for the fourth quarter of 2025. The revenue boost positively impacted the company’s share price, highlighting the market’s response to its sales performance.
Currently, MIRM’s stock is priced at $92.22, showing a decrease of 15.10% with a change of $16.40. The stock has fluctuated between $90.26 and $100.19 today. Over the past year, it reached a high of $107.41 and a low of $36.88, indicating significant volatility in its trading pattern.
MIRM has a market capitalization of approximately $4.77 billion, reflecting its size and market presence. The trading volume for the day is 1,034,896 shares, indicating active investor interest. As Mirum continues to focus on its core strengths, the market will closely watch its performance and strategic developments.
